Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Postgraduate Medicine|March 6, 2010
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL studyJosé Zamorano, Serap Erdine, Abel Pavia Lopez, et al.The Journal of Clinical Psychiatry|June 16, 2012
A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorderJill M Williams, Robert M Anthenelli, Chad D Morris, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 19, 2019
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal AntibodiesEllen Q Wang, Jack F Bukowski, Carla Yunis, et al.American Journal of Therapeutics|April 26, 2013
Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trialsJames H Ware, George W Vetrovec, Alan B Miller, et al.NPJ Primary Care Respiratory Medicine|May 21, 2014
Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialThierry Troosters, Frank C Sciurba, Marc Decramer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancerArkadiusz Z Dudek, Carla Yunis, Lester I Harrison, et al.Journal of Clinical Lipidology|April 25, 2018
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumabPaul M Ridker, Lynda M Rose, John J P Kastelein, et al.BMJ Open|March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) studyNeeta B Amin, Amanda Darekar, Quentin M Anstee, et al.Clinical and Experimental Hypertension (New York, N.Y. : 1993)|June 12, 2003
The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine valuesFrancisco Rodríguez-Esparragón, Octavio Hernández-Perera, José C Rodríguez-Pérez, et al.The New England Journal of Medicine|July 17, 2024
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19Jennifer Hammond, Carla Yunis, Robert J Fountaine, et al.Pageof 5